As of August 5th, 2022, an outbreak has been declared in CAMH’s Emergency Department, located at 1051 Queen Street West due to staff positive COVID-19 cases. This declaration was made in conjunction with Toronto Public Health, CAMH’s Health, Safety and Wellness (HSW), and Infection Prevention and Control (IPAC). The Emergency Department remains open to new patients. However, please advised that wait times might be longer than usual given staffing issues. CAMH has completed contact tracing for all impacted staff and confirmed that no patients have been exposed.
Research in the Schizophrenia Division is broad and includes studies on improving therapeutic and assessment approaches, management of side effects, enhancing patient recovery, as well identifying risk factors and causes to intervene early and develop new treatments. Our core research faculty has diverse interests and expertise in clinical treatment trials, metabolic risks, psychopharmacology, virtual reality, genetics and pharmacogenetics, neuropsychology, brain physiology and imaging, molecular biology and neuroinformatics. Together, we have created a research program that exemplifies a modern, translational approach to research on schizophrenia with the aim of better understanding, treating and preventing schizophrenia.
Research Areas & Projects
Current projects and key areas of research in the Schizophrenia Clinical Division include:
Metabolic risk management
Genetics and pharmacogenetics
Youth psychosis and at-risk populations
Recovery and rehabilitation
Visit our Programs & Services Directory for information on clinical care, including youth psychosis prevention, early psychosis, inpatient and outpatient services and more.